MAIA Biotechnology, Inc.
MAIA · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | -0.16 | -0.13 | 0.08 |
| FCF Yield | -7.58% | -9.92% | -7.55% | -5.25% |
| EV / EBITDA | -8.59 | -5.81 | -11.72 | -21.37 |
| Quality | ||||
| ROIC | -86.07% | -79.70% | -79.13% | -74.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.39 | 0.77 | 0.93 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 1.59% | -7.53% | -10.88% | 24.76% |
| Safety | ||||
| Net Debt / EBITDA | 1.96 | 2.00 | 2.67 | 3.18 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -49,270.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |